Michael Havert, PhD

Dr. Havert is a scientist with regulatory experience in developing gene therapies for the treatment of rare diseases and cancer. Fifteen years of experience in the FDA Division of Cell and Gene Therapies reviewing complex and emerging gene therapy medical products including regenerative medicine advanced therapy products. Expert reviewer for virus-based technologies, genetically modified cells, and therapeutic vaccines. Executive level regulatory experience in the industry. Leading product development efforts to ensure the safety and efficacy of investigational new drugs during a time of rapid expansion and change in the field of genetic medicine.